key: cord-0840505-nxd64im3
authors: Zhou, Yu-Jie; Zheng, Kenneth I.; Wang, Xiao-Bo; Yan, Hua-Dong; Sun, Qing-Feng; Pan, Ke-Hua; Wang, Ting-Yao; Ma, Hong-Lei; Chen, Yong-Ping; George, Jacob; Zheng, Ming-Hua
title: Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis
date: 2020-04-26
journal: J Hepatol
DOI: 10.1016/j.jhep.2020.04.027
sha: 2d71b74ea44812becf91e0b5ada6e95303c86442
doc_id: 840505
cord_uid: nxd64im3

nan

. [1] Metabolic and cardiovascular comorbidities like diabetes and hypertension aggravate the severity of COVID-19. [2] Another comorbidity, MAFLD, also affects COVID-19 severity, as pointed out by Ji et al.. Since excess liver fat is seen in up to a quarter of people, [3] we hypothesized that its impact on severity might be modulated by age. We considered that disease severity of older patients with a greater burden of cardiac and respiratory illness would more likely be impacted by their comorbid conditions, than the presence of liver fat. In this study, we investigated the effects of MAFLD on COVID-19 severity in older versus younger patients.

We consecutively recruited 327 adult patients (≥18 years old) with COVID-19 from four centers (the First Affiliated Hospital of Wenzhou Medical University, Wenzhou Central Hospital, Ningbo No.2 Hospital, and Ruian People's Hospital) in China, from 1 st January 2020 to 29 th February 2020. COVID-19 was diagnosed by high-throughput sequencing or RT-PCR assay of oropharyngeal swab specimens. Some of these patients were the subject of a previous report. [4] All subjects underwent screening for fatty liver by computed tomography. MAFLD was diagnosed based on the recent consensus criteria. [5, 6] Overweight was defined as body mass index (BMI) ≥23 kg/m 2 , and obesity was defined as BMI ≥25 kg/m 2 in Asians. [7] Diabetes mellitus was diagnosed based on the history or hemoglobin A1c ≥6.5%. [8] Hypertension was defined as blood pressure ≥130/85 mmHg or specific drug treatment. The requirement for written informed consent was waived by the ethics committees of all four centers due to the emergent epidemic and the anonymized retrospective nature of the analysis.

All demographic and laboratory parameters were collected on the day of admission.

COVID-19 severity was evaluated during hospitalization and divided into four subtypes namely mild, moderate, severe and critical illness in line with management guidelines in China. We defined mild and moderate COVID-19 subtypes as 'non-severe COVID-19', and severe and critically ill subtypes as 'severe COVID-19'.

All subjects received standard medical treatment according to the COVID-19 management guidance (7 th edition). [9] Seventy-four patients (22.6%) were elderly (i.e. more than 60 years of age) and 93 patients (28.4%) had MAFLD. In patients younger than 60 years, hypertension occurred in 45 (17.3%) patients, and diabetes were noted in 29 (11.2%) patients. In patients older than 60 years, there were 32 (43.2%) cases of hypertension and 18 (24.3%) of diabetes; this was significantly higher than in younger patients (P <0.001 and P=0.004, respectively). In contrast to the findings in younger patients (age <60 years), no significant difference in C-reactive protein, prevalence of diabetes and hypertension, or blood lipids was observed between non-MAFLD and MAFLD groups in elderly patients (all P >0.05). Moreover, an association between presence of MAFLD and COVID-19 severity was only observed in younger (Chi-square test P = 0.001), but not in elderly patients (Chi-square test P = 0.66).

MAFLD patients comprised 24.2% of the younger and 30.6% of the elderly cohort with non-severe COVID-19 (P=0.35), and 55.9% of the younger and 24% of the elderly patients with severe COVID-19 (P=0.01). Considering the effects of confounding bias, we performed multivariable logistic regression analyses ( Table 1 ).

In patients aged younger than 60 years, a more than two-fold higher prevalence of severe COVID-19 was observed in MAFLD patients compared to those without; this association remained significant after adjusting for age, sex, smoking status, overweight, diabetes, and hypertension (adjusted-OR 2.67, 95%CI 1.13-6.34, P=0.03).

In contrast, MAFLD was not associated with disease severity in multivariable analysis in elderly patients (P >0.05). We performed sensitivity analysis by setting a cut-off point other than 60 years to define younger and elderly patients. Similar results were observed at cut-offs using 55 and 65 years.

This multi-center study (COVID-MAFLD-CHESS) establishes a synergistic effect of MAFLD for severe COVID-19 in patient aged less than 60 years. The exact mechanism(s) underlying the age-dependent relationship is uncertain. Previous research has noted cellular immune dysregulation in COVID-19. [10] Thus, it might be postulated that hepatic and systemic immune responses caused by MAFLD [11] contributes to the cytokine storm in younger patients with COVID-19. In the elderly however, other comorbidities like coronary heart disease and chronic obstructive pulmonary disease are more prevalent and any association with MAFLD might be masked by their impact. [2] A notable limitation of our study was the smaller sample size of the older cohort of patients, which might influence the validity of the results. When 60 years was set as 

Implication of non-alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis

Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. The European respiratory

Non-alcoholic fatty liver disease -A global public health perspective

Obesity is a risk factor for greater COVID-19 severity

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease

A new definition for metabolic associated fatty liver disease: an international expert consensus statement

Obesity and Overweight in Asian People

Diagnosis of diabetes mellitus using HbA1c in Asians: relationship between HbA1c and retinopathy in a multiethnic Asian population

National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7

Clinical and immunologic features in severe and moderate Coronavirus Disease

The Immune Landscape in Nonalcoholic